The U.S. Court of Appeals for the Fifth Circuit denied a Reglan manufacturer's argument that federal law prohibits consumers from filing failure-to-warn claims. The decision, handed down on January 8, 2010, is a big win for patients injured by Reglan.
Actavis, Inc., a manufacturer of a generic Reglan, argued that users of a specific generic Reglan (metoclopramide) had no legal right to file claims. The court disagreed and dismissed the case, finding the claim has merit. The injured patient in that case suffers from tardive dyskinesia, a disorder that causes involuntary and repetitive movements.
Click here to read the court's opinion.
-DLF
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment